The Transformative Role of Biotechnology In Vaccine Development
Main Article Content
Abstract
Vaccines are biological substances that stimulate the body’s immune system and is one of the most effective public health tools for preventing infectious diseases. Biotechnology has improved vaccine development by transforming the field from traditional, empirical approaches to rational, antigen-specific design. This review evaluates the historical, traditional and the fundamental role of modern vaccine development, which have provided speed, scalability, and enhanced safety in combating infectious diseases. The key biotechnological innovations, which include recombinant subunit technology, mRNA vaccines, viral vectors systems, peptide-based vaccines, and nanoparticle delivery system have been analyzed for their mechanism, production efficiency, and capacity to induce strong immune response. These innovations enhance vaccine design, production, storage, and delivery. This paper further discusses biotechnology’s role in addressing global health emergencies, the challenges faced in implementation, and future trends such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) -based gene editing and AI-driven vaccine development through in silico antigen optimization. Finally, the force of the impact of biotechnology on vaccine development requires continued investment in research, fostering global collaboration to ensure these life-saving innovations are universally accessible and remain the cornerstone of improved global public health security.
Article Details
How to Cite
Josiah, J. G., Gofwen, N. J., Tswanya, M. N., & Idakwo, J. (2026). The Transformative Role of Biotechnology In Vaccine Development. The Bioscientist Journal, 14(1), 133-144. https://doi.org/10.54117/the_bioscientist.v14i1.210
Section
Articles
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Arash K. A., Julia W., Milad S., Emmanuel C., Stacie C., Niloofar G., Jennifer C., Elena D., Brendan K., Hani G., & ,Jiann S. Y. (2020). Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development. Front. Artif. Intell., 3: 65 -| https://doi.org/10.3389/frai.2020.00065.
Barrangou, R., & Doudna, J. A. (2016). Applications of CRISPR technologies in research and beyond. Nature Biotechnology, 34(9): 933-941. https://doi.org/10.1038/nbt.3659.
BBC News. (2021). Zydus Cadila: India approves world’s first DNA Covid vaccine. Retrieved from https://www.bbc.com/news/world-asia-india-57774294.
Bublot, M. (2023). Poultry Vaccine Technology Platforms. Avian Diseases. https://doi.org/10.1637/aviandiseases-d-23-99987 Centers for Disease Control and Prevention (CDC). (2019). Whooping cough vaccines. Retrieved from https://www.cdc.gov/pertussis/vaccines.html
Centers for Disease Control and Prevention (CDC). (2023). Novavax COVID-19 vaccine: What you need to know. Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/novavax.html
Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. S. (2021). Personalized mRNA vaccines: A new paradigm in cancer immunotherapy. Molecular Therapy, 29(2), 611-622. https://doi.org/10.1016/j.ymthe.2020.10.004
Chavda, V. P., Balar, P. C. and ; Apostolopoulos, V. (2024). History of vaccination, (pp. 1–12). Elsevier BV. https://doi.org/10.1016/b978-0-443-18564-9.00028-x
Barrangou, R., & Doudna, J. A. (2016). Applications of CRISPR technologies in research and beyond. Nature Biotechnology, 34(9): 933-941. https://doi.org/10.1038/nbt.3659.
BBC News. (2021). Zydus Cadila: India approves world’s first DNA Covid vaccine. Retrieved from https://www.bbc.com/news/world-asia-india-57774294.
Bublot, M. (2023). Poultry Vaccine Technology Platforms. Avian Diseases. https://doi.org/10.1637/aviandiseases-d-23-99987 Centers for Disease Control and Prevention (CDC). (2019). Whooping cough vaccines. Retrieved from https://www.cdc.gov/pertussis/vaccines.html
Centers for Disease Control and Prevention (CDC). (2023). Novavax COVID-19 vaccine: What you need to know. Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/novavax.html
Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. S. (2021). Personalized mRNA vaccines: A new paradigm in cancer immunotherapy. Molecular Therapy, 29(2), 611-622. https://doi.org/10.1016/j.ymthe.2020.10.004
Chavda, V. P., Balar, P. C. and ; Apostolopoulos, V. (2024). History of vaccination, (pp. 1–12). Elsevier BV. https://doi.org/10.1016/b978-0-443-18564-9.00028-x
Chinazzi, M., Davis, J. T., Ajelli, M., Gioannini, C., Litvinova, M., Merler, S., Pastore, Y., Piontti, A., Mu, K., Rossi, L., Sun, K., Viboud, C., Xiong, X., Yu, H., Halloran, M. E., Longini, I. M., & Vespignani, A. (2020). The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science, 368(6489), 395-400. https://doi.org/10.1126/science.aba9757.
Cohen, J. (2022). A universal coronavirus vaccine may be on the horizon. Science, 375(6578), 156-157. https://doi.org/10.1126/science.acz9818.
Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W., & Mastrobattista, E. (2021). Addressing the cold reality of mRNA vaccine stability. Journal of Pharmaceutical Sciences, 110(3), 997-1001. https://doi.org/10.1016/j.xphs.2020.12.006.
Erbelding, E. J., Post, D. J., Stemmy, E. J., Roberts, P. C., Augustine, A. D., Ferguson, S., & Graham, B. S. (2018). A universal influenza vaccine: The strategic plan for the National Institute of Allergy and Infectious Diseases. Journal of Infectious Diseases, 218(3), 347-354. https://doi.org/10.1093/infdis/jiy103.
Francis, M. J. (2017). Recent Advances in Vaccine Technologies. Veterinary Clinics of North America-Small Animal Practice; 8 (2): 231–241. https://doi.org/10.1016/J.CVSM.2017.10.002
Frazer, I. H. (2014). Development and implementation of papilloma virus prophylactic vaccines. The Journal of Immunology 192(9): 4007-4011.
Greenwood, B. (2014). The contribution of vaccination to global health: Past, present and future. Philosophical Transactions of the Royal Society B: Biological Sciences, 369(1645), 20130433. https://doi.org/10.1098/rstb.2013.0433
Hsu, J. L. (2013). A brief history of vaccines: smallpox to the present. South Dakota Medicine: The Journal of the South Dakota State Medical Association 33–37. https://pubmed.ncbi.nlm.nih.gov/23444589/
Hussein, I., Chams, N., Chams, S., Sayegh, S., Badran, R., Raad, M., Gerges-Geagea, A., Leone, A.; Jurjus, A. (2015). Vaccines Through Centuries: Major Cornerstones of Global Health Frontiers in Public Health, 3:269. https://doi.org/10.3389/FPUBH.2015.00269
Kailaje, V. (2024). Application of recombinant DNA technology for the development of vaccines in the field of virology, an overview, (pp. 124–127). https://doi.org/10.58532/v3bgbt2p2ch2 Kowalzik, F., Schreiner, D., Jensen, C., Teschner, D., Gehring, S., & Zepp, F. (2021). mRNA-based vaccines: A new era in vaccinology. Allergo Journal International, 30(6), 263-272. https://doi.org/10.1007/s40629-021-00178-2
Kowalzik, F., Schreiner, D., Jensen, C., Teschner, D., Gehring, S., & Zepp, F. (2021). mRNA-based vaccines: A new era in vaccinology. Allergo Journal International, 30(6), 263-272. https://doi.org/10.1007/s40629-021-00178-2.
Kusters I., Almond, J. W. (2008) Vaccine Strategies. Encyclopedia of Virology; :235–243. doi: 10.1016/B978-012374410-4.00597-5
Larson, H. J., de Figueiredo, A., Xiahong, Z., Schulz, W. S., Verger, P., Johnston, I. G., … & Jones, N. S. (2016). The state of vaccine confidence 2016: Global insights through a 67-country survey. EBioMedicine, 12, 295-301. https://doi.org/10.1016/j.ebiom.2016.08.042.
Lipsitch, M., & Eyal, N. (2017). Improving vaccine trials in infectious disease emergencies. Science, 357(6357), 153-156. https://doi.org/10.1126/science.aam8334.
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing Covid-19 vaccines at pandemic speed. New England Journal of Medicine, 382(21), 1969-1973. https://doi.org/10.1056/NEJMp2005630.
Matthew B., Amanda, T., Matthew, T. & Colleen, O. (2010) Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists. Expert Rev Vaccines. 9(2):157–173. doi: 10.1586/erv.09.160.
McLean, K. A., Goldin, S., Nannei, C., Sparrow, E., & Torelli, G. (2016). The 2015 global production capacity of seasonal and pandemic influenza vaccine. Vaccine, 34(45), 5410-5413. https://doi.org/10.1016/j.vaccine.2016.08.019.
Moderna. (2024). mRNA-1273: The Moderna COVID-19 vaccine. Retrieved from https://www.modernatx.com.
Morrow, M. P., Kraynyak, K. A., Sylvester, A. J., Shen, X., Amante, D. H., Walter, K. L., Boyer, J. D., & Weiner, D. B. (2020). DNA vaccine approaches in human immunotherapy and prophylaxis. Human Vaccines & Immunotherapeutics, 16(2), 488-497. https://doi.org/10.1080/21645515.2019.1649539.
Muodiaju J C, Madu C S (May 26, 2025) Messenger Ribonucleic Acid (mRNA)-Based Universal Vaccines: Engineering Broad-Spectrum Immunity Against Future Pandemics. Cureus 17(5): e84821. doi:10.7759/cureus.84821.
National Institute of Allergy and Infectious Diseases (NIAID). (2016). Zika Virus Vaccines. Retrieved from https://www.niaid.nih.gov/diseases-conditions/zika-vaccines.
Nature Medicine. (2002). Edible vaccines: Not quite ready for prime time. Retrieved from https://www.nature.com/articles/nm0202-94.
O’Hagan, D. T., De Gregorio, E. (2009). The path to a successful vaccine adjuvant – ‘the long and winding road’. Drug Discov Today;14(11–12):541–551. doi: 10.1016/j.drudis.2009.02.009.
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261-279. https://doi.org/10.1038/nrd.2017.243
Philippon, A. (2023). La saga des vaccins à ARNm. Bulletin De L Academie Veterinaire De France,176 (1): 326–329.https://doi.org/10.3406/bavf.2023.18300
Plotkin, S. A. (2018). History of vaccination. Proceedings of the National Academy of Sciences, 111(34), 12283-12287. https://doi.org/10.1073/pnas.1400472111.
Poland, G. A., Ovsyannikova, I. G., & Kennedy, R. B. (2018). Personalized vaccinology: A review. Vaccine, 36(36), 5350-5357. https://doi.org/10.1016/j.vaccine.2017.07.062
Poria, R., Kala, D., Nagraik, R., Dhir, Y., Dhir, S., Singh, B., Kaushik, N. K., Noorani, Md. S., Kaushal, A., & Gupta, S. (2023). Vaccine development: Current trends and technologies. Life Science. https://doi.org/10.1016/j.lfs.2023.122331.
Rai, C.-I., Kuo, T.-H., & Chen, Y. (2024). Novel Administration Routes, Delivery Vectors, and Application of Vaccines Based on Biotechnologies: A Review. Vaccines, 12(9), 1002. https://doi.org/10.3390/vaccines12091002.
Rappuoli, R., Bloom, D. E., & Black, S. (2019). Vaccines and global health: In search of a sustainable model for vaccine development. Nature Medicine, 25(2), 171‐178.
Riedel, S. (2005). Edward Jenner and the history of smallpox and vaccination. Baylor University Medical Center Proceedings, 18(1), 21-25. https://doi.org/10.1080/08998280.2005.11928028.
Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J. T., & Alves, P. M. (2010). Virus-like particles in vaccine development. Expert Review of Vaccines, 9(10), 1149-1176. https://doi.org/10.1586/erv.10.115.
Rouphael, N. G., Paine, M., Mosley, R., Henry, S., Benkeser, D., Lu, H., Kalluri, H., Vassilieva, E., Kourtis, A. P., Barke, L., Scott, J., Sherwood, R., Kabbani, S., Lai, L., Alston, B., Papanicolaou, G., Shrestha, R., Cioce, V., Skountzou, I., …& Sullivan, N. L. (2017). The safety, immunogenicity, and acceptability of an inactivated influenza vaccine delivered by microneedle patch: A randomized, partly blinded, placebo-controlled trial. The Lancet, 390(10095), 649-658. https://doi.org/10.1016/S0140-6736(17)30575-5.
The Scientist. (2022). Canada approves world’s first plant-based COVID-19 vaccine. Retrieved from https://www.the-scientist.com/news-opinion/canada-approves-worlds-first-plant-based-covid-19-vaccine-69745.
Tushar D. (2024). Biotechnology In Vaccines. Tech Horizons: Bridging Disciplines in the Era of Emerging Technologies e-ISBN: 978-93-6252-486-7 IIP Series pp 6-10.
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., … & Oxford COVID Vaccine Trial Group. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111. https://doi.org/10.1016/S0140-6736(20)32661-1.
Wang, J., Peng, Y., Xu, H., & Cui, Z. (2021). Calcined cold chain logistics: Challenges and solutions. Vaccine, 39(5), 782‐790.
Wardi, B. J., Gobeil, P., Séguin, A., Atkins, J., Boulay, I., Charland, N., Couture, M., D’Aoust, M. A., Dhaliwall, J., Finkle, C., Hager, K., Huang, B., Jiang, H., Landry, N., Lano, R., Li, X., Loeb, M., Makarkov, A.,… & Vézina, L. P. (2021). Phase 1 trial of a plant-derived virus-like particle vaccine for COVID-19. Nature Medicine, 27(6), 1071-1078. https://doi.org/10.1038/s41591-021-01370-1.
World Health Organization (WHO). (2020). Smallpox eradication: A public health success story. Retrieved from https://www.who.int/news-room/fact-sheets/detail/smallpox.
World Health Organization (WHO). (2021). Global vaccine market report. Retrieved from https://www.who.int/publications-detail/global-vaccine-market-report.
World Health Organization (WHO). (2021). Global vaccine market report. Retrieved from https://www.who.int/publications-detail/global-vaccine-market-report.
Zhang, X., Zhao, Q., Huang, Y., Wang, J., Li, W., Wang, H., & Yang, S. (2022). Advances in nanotechnology-based vaccine delivery systems against infectious diseases. Frontiers in Immunology, 13, 945523. https://doi.org/10.3389/fimmu.2022.945523.
Zhao, L., Seth, A., Wibowo, N., Zhao, C. X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014). Nanoparticle vaccines. Vaccine, 32(3), 327-337. https://doi.org/10.1016/j.vaccine.2013.11.069.
Zhongbiao, F., Jingting L., Jianhua, L., Chaonan, L., Yuxuan, Z., Yikai, G., Ying, W., Yanjun, Z., & Keda, C. (2022). Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects, Front Bioeng Biotechnol, 9;10:921755. doi: 10.3389/fbioe.2022.921755.